We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Compound Enhances Skeletal Tissue Regeneration

By LabMedica International staff writers
Posted on 08 Apr 2013
Print article
New cutting-edge research revealed how a novel low-molecular-weight compound enhances ectopic bone formation and fracture repair.

The study, by investigators from conducted by the Atlanta Veterans Affairs Medical Center (GA, USA) and Emory University School of Medicine (Atlanta, GA, USA), was conducted to design and evaluate small molecules that could enhance recombinant human bone morphogenetic protein-2 (rhBMP-2) responsiveness. The investigation used two models to assess the ability of a small synthetic molecule to optimize bone formation in a rodent ectopic model and to determine whether an injection of that molecule accelerate callus formation in a rodent femoral fracture model.

The findings revealed that a single dose of the small molecule enhanced bone healing in the ectopic model combined with the occurrence of low-dose exogenous rhBMP-2, and in the femoral fracture model with the presence of only naturally occurring BMPs. The study’s findings, published in March 6, 2013, in the Journal of Bone and Joint Surgery.

SkelRegen, LLC (West Chester, PA, USA) is the first company to focus on newly identified small molecules that target different aspects of the skeletal tissue formation pathway. The study’s findings serves as additional confirmation that by following established procedures, SkelRegen continues to work on research to regenerate bone from scratch. “While our work on skeletal tissue regeneration is far from complete, this study exemplifies that research is continuing and SkelRegen technology is at the forefront,” said Stephen LaNeve, SkelRegen’s cofounder and CEO. “Our partnership with Emory University makes it possible for us to be part of such revolutionary work.”

Boden, SkelRegen’s cofounder and chief medical, science and technology officer, said, “The process was long and arduous and would not have been possible without the computational design work of the Emory/VA team led by Sree Sangadala, PhD But, ultimately these results further demonstrate how bone regeneration with small molecules will transform musculoskeletal care.”

SkelRegen identified not one, but multiple small molecules that are osteoinductive and target different features of the skeletal tissue formation pathway. All of the compounds are inexpensive to manufacture and many of the compounds are clear for other uses by the US Food and Drug Administration (FDA), therefore, they already have acceptable safety and toxicity profiles.

Related Links:

Atlanta Veterans Affairs Medical Center
Emory University School of Medicine
Regen


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.